valine has been researched along with mdv 3100 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Du, Z; Hao, Y; Li, L; Li, T; Liu, N; Luo, C; Quan, Z; Sun, W; Wang, J; Wang, X; Wu, X; Yuan, M; Zhang, Y | 1 |
| Ahmad, N; Cheng, L; Farah, E; Kong, Y; Lanman, NA; Li, C; Li, L; Liu, X; Lorenz, GR; Pascuzzi, P; Ratliff, T; Zhang, Y | 1 |
2 other study(ies) available for valine and mdv 3100
| Article | Year |
|---|---|
HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in
Topics: Adult; Aged; Amyloid Precursor Protein Secretases; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms, Castration-Resistant; Proteins; Receptors, Notch; Signal Transduction; Taxoids; Tetrahydronaphthalenes; Valine; Xenograft Model Antitumor Assays | 2018 |
NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.
Topics: Animals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Receptor, Notch1; Receptor, Notch2; Signal Transduction; Tetrahydronaphthalenes; Transcription Factor HES-1; Valine; Xenograft Model Antitumor Assays | 2019 |